NCT05293158View on ClinicalTrials.gov

Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study

NANot yet recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Hepatocellular CarcinomaHBV
Interventions
DRUG

Hepatect CP 50 I.E./ml infusion solution

"Application of i.v. (intravenously) HBIGs for ≥6-weeks:~Day (D) 0-7: 10.000 IU D14 until end-of-treatment: 10.000 IU once per week HBIGs will be given until LT/liver resection."

All Listed Sponsors
lead

Medical University of Graz

OTHER